Abstract Fat mass, once viewed primarily as a passive energy reservoir, is now recognized as a dynamic endocrine organ with profound implications for metabolic health, aging, and disease. Recent breakthroughs in single-cell genomics, lipidomics, and bioengineering have transformed our understanding of adipose tissue heterogeneity, plasticity, and communication with other organs. This review highlights cutting-edge discoveries in fat mass regulation, including the identification of novel adipocyte subtypes, the role of lipid droplet-associated proteins in metabolic flexibility, and the emergence of precision interventions targeting adipose dysfunction.

1. Introduction Excess fat mass, particularly visceral and ectopic lipid accumulation, is a hallmark of obesity and a major risk factor for type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. However, not all fat is detrimental: subcutaneous and brown/beige adipocytes exert protective metabolic effects. The dichotomy between "healthy" and "unhealthy" fat mass has driven a surge in research aimed at deciphering the molecular underpinnings of adipose tissue remodeling. In the past three years, technological innovations have unveiled previously unrecognized layers of complexity in fat mass biology.

2. Single-Cell Resolution of Adipose Tissue Heterogeneity A landmark study by Emont et al. (2022) utilized single-nucleus RNA sequencing (snRNA-seq) to map the cellular landscape of human subcutaneous and visceral adipose tissue. The analysis identified distinct subtypes of adipocytes, including a novel "lipid-associated macrophage (LAM)" population that expresses high levels ofTREM2andLPL. These LAMs are enriched in obese adipose tissue and appear to facilitate lipid scavenging and remodeling. Concurrently, a separate study by Sun et al. (2023) revealed that adipocyte progenitor cells (APCs) exhibit depot-specific transcriptional programs, with visceral APCs displaying a pro-fibrotic signature that may explain the pathological rigidity of visceral fat. These findings challenge the traditional view of adipocyte uniformity and open avenues for cell-type-specific therapeutic targeting.

3. Lipid Droplet Dynamics and Metabolic Flexibility The lipid droplet (LD) is the central organelle governing fat mass storage and mobilization. Recent work by Thiam et al. (2023) elucidated the role of the protein seipin in LD biogenesis. Using cryo-electron tomography, they demonstrated that seipin oligomers form a funnel-like structure that facilitates the nucleation of neutral lipids at the endoplasmic reticulum membrane. Mutations inBSCL2(encoding seipin) cause congenital generalized lipodystrophy, a condition characterized by near-total loss of fat mass. In parallel, research on perilipin family proteins (PLIN1-5) has advanced our understanding of lipolysis regulation. A 2024 study by Granneman et al. showed that PLIN5 acts as a molecular brake on lipolysis in oxidative tissues, protecting against lipid-induced mitochondrial dysfunction. These insights are driving the development of small-molecule modulators of LD proteins for treating lipodystrophy and obesity.

4. Inter-Organ Communication via Adipose-Derived Extracellular Vesicles Adipose tissue secretes a vast array of signaling molecules, including adipokines, exosomes, and microRNAs. A breakthrough in 2023 by Zhang et al. demonstrated that extracellular vesicles (EVs) from obese adipose tissue carry specific microRNA cargo (e.g., miR-27a, miR-222) that can directly impair insulin signaling in hepatocytes and myocytes. Conversely, EVs from brown adipose tissue (BAT) have been shown to transfer functional mitochondria to recipient cells, enhancing systemic energy expenditure (Cypess et al., 2024). This EV-mediated crosstalk suggests that fat mass influences distal organs beyond classical endocrine pathways, offering a new frontier for biomarker discovery and therapeutic delivery.

5. Technological Breakthroughs in Fat Mass Quantification and Modulation Accurate measurement of fat mass distribution is critical for both research and clinical practice. Advanced imaging techniques, such as quantitative Dixon MRI and dual-energy X-ray absorptiometry (DXA), now provide depot-specific fat mass quantification with high precision. On the therapeutic front, the development of "cold-mimetic" drugs that activate BAT without actual cold exposure has progressed significantly. The β3-adrenergic receptor agonist mirabegron, originally approved for overactive bladder, has been repurposed to increase BAT activity and reduce white fat mass in humans (O’Mara et al., 2023). Moreover, CRISPR-based gene editing has been applied to convert white adipocytes to a beige phenotypein vivoby targetingPRDM16orUCP1regulatory elements (Wang et al., 2024). These approaches, while still in preclinical stages, herald a new era of "adipose reprogramming" strategies.

6. Future Directions and Challenges Despite these advances, several critical questions remain. How do we reconcile the beneficial effects of beige fat expansion with the potential for ectopic lipid deposition? Can we develop therapies that selectively reduce pathogenic visceral fat while preserving or even expanding protective subcutaneous depots? The integration of multi-omics data with artificial intelligence may enable the identification of personalized "adipose signatures" that predict metabolic risk and treatment response. Furthermore, the translation of adipose biology into clinical practice requires robust biomarkers for early detection of adipose dysfunction. Circulating lipid species, such as ceramides and diacylglycerols, are emerging as strong candidates (Hammond et al., 2024).

Conclusion The past five years have witnessed a paradigm shift in our understanding of fat mass, moving from a static storage concept to a dynamic, heterogeneous, and communicatory system. The convergence of single-cell technologies, structural biology, and gene-editing tools is paving the way for precision interventions that could mitigate the global burden of obesity-related diseases. As we continue to unravel the molecular logic of adipose tissue, the promise of "healthy fat" as a therapeutic target becomes increasingly tangible.

References